The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments-Reference-Cited by-同舟云学术

The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments

Published:2011-03-02 Issue:1 Volume:12 Page:
ISSN:1745-6215
Container-title:Trials
language:en
Short-container-title:Trials

Author:

Connick Peter,Kolappan Madhan,Patani Rickie,Scott Michael A,Crawley Charles,He Xiao-Ling,Richardson Karen,Barber Kelly,Webber Daniel J,Wheeler-Kingshott Claudia AM,Tozer Daniel J,Samson Rebecca S,Thomas David L,Du Ming-Qing,Luan Shi L,Michell Andrew W,Altmann Daniel R,Thompson Alan J,Miller David H,Compston Alastair,Chandran Siddharthan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Link

http://link.springer.com/article/10.1186/1745-6215-12-62/fulltext.html

Reference29 articles.

1. Compston DAS, Coles AJ: Multiple Sclerosis. Lancet. 2008, 372: 1502-1517. 10.1016/S0140-6736(08)61620-7.

2. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R, BENEFIT Study Group: Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007, 370: 389-97. 10.1016/S0140-6736(07)61194-5.

3. CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK: Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008, 359: 1786-801. 10.1056/NEJMoa0802670.

4. Rivera FJ, Couillard-Despres S, Pedre X, Ploetz S, Caioni M, Lois C, Bogdahn U, Aigner L: Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural stem cells. Stem Cells. 2006, 24: 2209-19. 10.1634/stemcells.2005-0614.

5. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, Miller RH: Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. 2009, 57: 1192-203. 10.1002/glia.20841.

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of mesenchymal stem cells in attenuating inflammatory bowel disease through ubiquitination;Frontiers in Immunology;2024-08-09

2. Mesenchymal stem cells in autoimmune disease: A systematic review and meta-analysis of pre-clinical studies;Biochimie;2024-08

3. Neural Cells for Neurodegenerative Diseases in Clinical Trials;Stem Cells Translational Medicine;2023-07-24

4. Current advances in stem cell therapy in the treatment of multiple sclerosis;Reviews in the Neurosciences;2022-12-12

5. Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis;Regenerative Therapy;2022-12